AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXThe company said total revenue for Q3 2025 was $3.08 billion, up 11% from Q3 2024. U.S. revenue rose 15% to $1.98 billion, and revenue outside the U.S. rose 4% to $1.10 billion.
Key points
AI summaryThe company said total revenue for Q3 2025 was $3.08 billion, up 11% from Q3 2024. U.S. revenue rose 15% to $1.98 billion, and revenue outside the U.S. rose 4% to $1.10 billion.
Vertex said GAAP net income for Q3 was $1.1 billion and non-GAAP net income was $1.2 billion, up from $1.0 billion and $1.1 billion a year earlier. The company said higher product revenue was partly offset by higher operating expenses.
The company set its full-year 2025 total revenue outlook at $11.9 to $12.0 billion, compared with its prior outlook of $11.85 to $12.0 billion. Its combined non-GAAP R&D, AIPR&D and SG&A expense outlook is $5.0 to $5.1 billion (previously $4.9 to $5.0 billion).
The company said cash, cash equivalents and total marketable securities as of September 30, 2025 were $12.0 billion, up from $11.2 billion as of December 31, 2024. It said the increase from operating cash flow was partly offset by share repurchases.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Vertex Q3 total revenue of $3.08 billion rises 11% year over year
The company said total revenue for Q3 2025 was $3.08 billion, up 11% from Q3 2024. U.S. revenue rose 15% to $1.98 billion, and revenue outside the U.S. rose 4% to $1.10 billion.
Source · Based on the filing body and exhibits
Vertex Q3 GAAP net income $1.1 billion as operating expenses rise
Vertex said GAAP net income for Q3 was $1.1 billion and non-GAAP net income was $1.2 billion, up from $1.0 billion and $1.1 billion a year earlier. The company said higher product revenue was partly offset by higher operating expenses.
Source · Based on the filing body and exhibits
Vertex sets full-year revenue outlook at $11.9 to $12.0 billion
The company set its full-year 2025 total revenue outlook at $11.9 to $12.0 billion, compared with its prior outlook of $11.85 to $12.0 billion. Its combined non-GAAP R&D, AIPR&D and SG&A expense outlook is $5.0 to $5.1 billion (previously $4.9 to $5.0 billion).
Source · Based on the filing body and exhibits
Cash and marketable securities at $12.0 billion as operating cash flow rises
The company said cash, cash equivalents and total marketable securities as of September 30, 2025 were $12.0 billion, up from $11.2 billion as of December 31, 2024. It said the increase from operating cash flow was partly offset by share repurchases.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…